Quarterly ResultAug 13, 2026, 05:23 PM
Oncotelic Q2 Net Loss $(1.81M); Going Concern Warning Issued
AI Summary
Oncotelic Therapeutics reported a net loss of $(1.81) million for the six months ended June 30, 2026, a significant increase from $(20,860) in the prior year, and issued a going concern warning. Despite the financial challenges, the company saw an increase in service revenue to $250,000 and made progress on strategic initiatives, including a Nasdaq uplisting application and a partnership with TechForce Robotics. Its joint venture, GMP Bio, is also advancing OT-101 towards Phase 2 and 3 trials.
Key Highlights
- Net loss attributable to Oncotelic Therapeutics, Inc. was $(1,805,629) for H1 2026, compared to $(20,860) for H1 2025.
- Company issued a going concern warning due to negative working capital of $16.4 million and negative cash flows from operations.
- Service revenue increased to $250,000 for H1 2026 from $0 in H1 2025.
- Total assets increased to $394,750,732 as of June 30, 2026, from $393,088,242 at December 31, 2025.
- Raised $0.5 million from the issuance of convertible debt instruments during H1 2026.
- Filed an initial application with Nasdaq on July 28, 2026, for uplisting.
- Entered a strategic partnership with TechForce Robotics for an AI-enabled, GMP-compliant robotics platform.
- Joint Venture (GMP Bio) continues preparing for planned Phase 2 and Phase 3 trials for OT-101.
Price Impact
More from OTLC